Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Documenti analoghi

• Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
  di: Cohen, Stanley B, et al.
  Pubblicazione: (2020)
• Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
  di: Curtis, Jeffrey R, et al.
  Pubblicazione: (2016)
• Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
  di: Jürgen Wollenhaupt, et al.
  Pubblicazione: (2019-04-01)
• Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
  di: Wollenhaupt, Jürgen, et al.
  Pubblicazione: (2019)
• Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
  di: Kaine, Jeffrey, et al.
  Pubblicazione: (2020)